[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US3531522A - 4'-phenoxyalkanesulfonanilides - Google Patents

4'-phenoxyalkanesulfonanilides Download PDF

Info

Publication number
US3531522A
US3531522A US654064A US3531522DA US3531522A US 3531522 A US3531522 A US 3531522A US 654064 A US654064 A US 654064A US 3531522D A US3531522D A US 3531522DA US 3531522 A US3531522 A US 3531522A
Authority
US
United States
Prior art keywords
aniline
chloride
inclusive
ethyl
phenoxymethanesulfonanilide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US654064A
Inventor
Norman A Nelson
Gary E Vanden Berg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of US3531522A publication Critical patent/US3531522A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/22—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing two or more pyridine rings directly linked together, e.g. bipyridyl

Definitions

  • the compounds of this invention are 4'-phenoxyalkanesulfonanilides which can be represented by the formula wherein X can be halo, alkyl containing from 1 to 4 carbon atoms, inclusive, or alkoxy containing from 1 to 4 carbon atoms, inclusive; Y can be halo; R can be hydrogen, alkyl containing from 1 to 4 carbon atoms, inclusive, 3-piperidinopropyl, 2-piperidinoethyl, 3-(l-pyrrolidinyl)propyl, 2-(1-pyrrolidinyl)ethyl, 3-morpholinopropyl, 2-morpholinoethyl and dialkylaminoalkyl of the formula R8 --(CH2)kN where R and R can be alike or difierent and are alkyl containing from 1 to 4 carbon atoms, inclusive; and R can be alkyl containing from 1 to 6 carbon atoms, inclusive.
  • the subscript k is an integer having a value of 2 or 3
  • m and n are integers having a value of zero to 3, inclusive, and of zero to 2, inclusive, respectively.
  • the instant compounds can be prepared by reacting a phenoxyaniline of the type O- NH Q Q l.
  • Xm Yn where X, Y, m and n have the same meaning as above and R is hydrogen or alkyl containing from 1 to 4 carbon atoms, inclusive, with an alkanesulfonyl halide represented by the formula (HI) HalogenSO -R where R has the same meaning as above, and Halogen preferably is chlorine or bromine.
  • halo radicals are fluoro, chloro, bromo, and iodo.
  • alkyl radicals contemplated herein are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.- butyl, tert.-butyl, the pentyls, and the hexyls.
  • Illustrative alkoxy radicals are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec.-butoxy, and tert.-butoxy.
  • phenoxyanilines represented by Formula II are a known group of compounds, some of which are commercially available.
  • Illustrative phenoxyanilines (II) are p- (p-chlorophenoxy aniline,
  • alkanesulfonyl halides of Formula III are also a known class of compounds, and some are commercially available. Methods of preparation can be found in I. Am. Chem. Soc. 58, 1348 (1936); J. Am. Chem. Soc. 59, 1837, 2439 (1937); and J. Am. Chem. Soc. 60, 1486 (1938).
  • Illustrative alkanesulfonyl halides (III) are methanesulfonyl chloride, ethanesulfonyl chloride, butanesulfonyl chloride, propanesulfonyl chloride, l-methylethanesulfonyl chloride, sec.-butanesulfonyl chloride, isobutanesulfonyl chloride, pentanesulfonyl chloride, hexanesulfonyl chloride, etc.
  • a 4-phenoxyalkanesulfonilide (I) where R is hydrogen can be alkylated by treatment, in an inert organic solvent such as benzene, tetrahydrofuran, or dioxane, with an alkylating agent which can be an alkyl halide or a sec.-aminoalkyl halide.
  • the alkylation takes place in the presencepf a base, for example, an alkali metal alkoxide such as potassium tert.-butoxide, or an alkali metal hydride such as sodium hydride or potassium hydride.
  • Reaction temperature for the alkylation reaction can range from about C. to about 100 C.
  • the alkylating agent is a primary alkyl iodide
  • room temperature is the preferred reaction temperature; however, for alkyl chlorides a temperature from about 50 C. to about 100 C. is preferred.
  • sec.-aminoalkyl halides in the form of a hydrohalide salt are employed as the alkylating agent, sufiicient base is added to the reaction mixture to liberate the free sec.-aminoalkyl halide and to form the sulfonanilide alkali metal salt.
  • alkyl halides which can be used as alkylating agents are methyl iodide, ethyl iodide, propyl iodide, butyl iodide, methtyl bromide, ethyl chloride, propyl bromide, butyl chloride, sec.-butyl bromide, and the like.
  • Illustrative sec.-aminoalkyl halides suitable as alkylating agents are N,N-diethyl-2-chloroethylamine, N,N- dibutyl-2-chloro-ethylamine, N,N diethyl-3-chloropropylamine hydrochloride, N-methyl-N-propyl-3-bromopropylamine hydrochloride, N ethyl N-butyl-2-bromoethylamine, N-(Z-chloroethyl)piperidine, N-(3-chloropropyl) piperidine, N-(2-chloroethyl)pyrrolidine, N-(S-chloropropyl)pyrrolidine, N-(2-chloroethyl)morpholine, N-(3- chloropropyl)morpholine, and the like.
  • R sec.-aminoalkyl
  • amines which can eXist either in the nonprotonated or free-base form, or in the protonated or acid addition salt form, depending on the pH of the environment.
  • Stable, pharmaceutically acceptable protonates can be formed on neutralization of the free-base form with suitable acids such as hydrogen chloride, hydrogen bromide, sulfuric acid, phosphoric acid, acetic acid, and the like.
  • the compounds of this invention have lipid-normalizing activity and thus are useful as hypocholesterolemic agents and as hypotriglyceridemic agents in mammals.
  • the amount of the active ingredient that is to be administered depends on the age, weight, and condition of the recipient, and also on factors such as the frequency and route of administration.
  • the daily dose range can be from about 0.1 milligram per kilogram of body weight to about 50 milligrams per kilogram of body weight.
  • the resulting admixture was stirred at about room temperature for about 4 hours, then diluted with water and ice. A precipitate was observed to form and was recovered by filtration. Upon recrystallization from methanol, about 35 grams of a product melting at 125 C. to 126 C., and about 9 grams of the same product melting at 124 C.
  • N-methyl-N-propyl-3-chloropropylamine hydrochloride the corresponding N-[3-(N-methyl-N-propylamino)propyl]-4'-phenoxymethanesulfonanilide can be prepared;
  • N-(2-chloroethyl)morpholine the corresponding N-(2-morpholinoethyl)-4' phenoxymethanesulfonanilide can be prepared;
  • X is a member of the grouping consisting of halo, alkyl containing from 1 to 4 carbon atoms, inclusive, and alkoxy containing from 1 to 4 carbon atoms, inclusive;
  • Y is halo;
  • R is dialkylaminoalkyl with R and R both ethyl and k has a value of 2, R is methyl, and mi and n have a value of zero.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

United States Patent O 3,531,522 4'-PHENOXYALKANESULFONAN]LIDES Norman A. Nelson, Charlestown Township, Kalamazoo County, and Gary E. Vanden Berg, Texas Township, Kalamazoo County, Mich., assignors to The Upjohn Company, Kalamazoo, Mich., a corporation of Delaware No Drawing. Filed July 18, 1967, Ser. No. 654,064 Int. Cl. A01n 9/16; C07c 143/74 US. Cl. 260-556 4 Claims ABSTRACT OF THE DISCLOSURE Disclosed are lipid-normalizing 4-phenoxyalkanesulfonanilides which are derived from p-phenoxyanilines.
BACKGROUND OF THE INVENTION In is known that relatively high serum cholesterol and triglyceride levels are injurious to arterial tissue, and that such injuries may be one of the causes of coronary heart disease and atherosclerosis. It has now been found that the serum lipid level in a mammal, and in particular the cholesterol and the triglyceride levels, can be lowered by administering to the mammal an effective amount of a compound of the present invention.
SUMMARY OF THE INVENTION The compounds of this invention are 4'-phenoxyalkanesulfonanilides which can be represented by the formula wherein X can be halo, alkyl containing from 1 to 4 carbon atoms, inclusive, or alkoxy containing from 1 to 4 carbon atoms, inclusive; Y can be halo; R can be hydrogen, alkyl containing from 1 to 4 carbon atoms, inclusive, 3-piperidinopropyl, 2-piperidinoethyl, 3-(l-pyrrolidinyl)propyl, 2-(1-pyrrolidinyl)ethyl, 3-morpholinopropyl, 2-morpholinoethyl and dialkylaminoalkyl of the formula R8 --(CH2)kN where R and R can be alike or difierent and are alkyl containing from 1 to 4 carbon atoms, inclusive; and R can be alkyl containing from 1 to 6 carbon atoms, inclusive. The subscript k is an integer having a value of 2 or 3, and m and n are integers having a value of zero to 3, inclusive, and of zero to 2, inclusive, respectively. The foregoing compounds are useful as hypocholesterolemic and hypotriglyceridemic agents.
DETAILED DESCRIPTION OF THE INVENTION The instant compounds can be prepared by reacting a phenoxyaniline of the type O- NH Q Q l.
Xm Yn where X, Y, m and n have the same meaning as above and R is hydrogen or alkyl containing from 1 to 4 carbon atoms, inclusive, with an alkanesulfonyl halide represented by the formula (HI) HalogenSO -R where R has the same meaning as above, and Halogen preferably is chlorine or bromine.
3,531,522 Patented Sept. 29, 1970 In Formulas I and II illustrative halo radicals are fluoro, chloro, bromo, and iodo.
Illustrative of the alkyl radicals contemplated herein are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.- butyl, tert.-butyl, the pentyls, and the hexyls.
Illustrative alkoxy radicals are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec.-butoxy, and tert.-butoxy.
The phenoxyanilines represented by Formula II are a known group of compounds, some of which are commercially available. Illustrative phenoxyanilines (II) are p- (p-chlorophenoxy aniline,
po-chlorophenoxy) aniline,
3 -chloro-4-phenoxyaniline,
4- p-chlorophenoxy) -3 ,5 -diiodoaniline, p- 2,4-dichlorophenoxy) aniline,
p- 2,5 -dichlorophenoxy) aniline,
p- (2,4-dibromophenoxy) aniline,
3,5 -diiodo-4-phenoxyaniline,
p- (p-bromophenoxy) aniline,
p- (p-iodophenoxy aniline,
p- (o-iodophenoxy) aniline, 3-iodo-4-phenoxyaniline,
pm-bromophenoxy) aniline,
p- 2,4,5 -trichlorophenoxy) aniline,
p- 2,4,6 -trichlorophenoxy) aniline,
p- (p-tert.-butylphenoxy) aniline, N-methyl-p-phenoxyaniline,
p- (p-tolyloxy) aniline,
p- 3,4-xylyloxy) aniline,
p- (p-methoxyphenoxy) aniline,
p- (m-methoxyphenoxy) aniline,
p- 3 ,5 -dimethoxyphenoxy) aniline,
p- (6-b romo-2,4-Xyly1oxy) aniline,
3 ,5 -diiodo-4- p-methoxyphenoxy) aniline, p (2,6-dimethoxyphenoxy) -N-isopropylaniline, N-sec.-butyl-pp-methoxyphenoxy) aniline, p-phenoxyaniline, and the like.
The alkanesulfonyl halides of Formula III are also a known class of compounds, and some are commercially available. Methods of preparation can be found in I. Am. Chem. Soc. 58, 1348 (1936); J. Am. Chem. Soc. 59, 1837, 2439 (1937); and J. Am. Chem. Soc. 60, 1486 (1938).
Illustrative alkanesulfonyl halides (III) are methanesulfonyl chloride, ethanesulfonyl chloride, butanesulfonyl chloride, propanesulfonyl chloride, l-methylethanesulfonyl chloride, sec.-butanesulfonyl chloride, isobutanesulfonyl chloride, pentanesulfonyl chloride, hexanesulfonyl chloride, etc.
The reaction between a phenoxyaniline (II) and an alkanesulfonyl halide (III) can be carried out by admixing one or more equivalents of the alkanesulfonyl halide with the phenoxy-aniline in a suitable reaction medium which is also an acid acceptor for the hydrogen halide formed during the reaction, such as pyridine, the alkylsubstituted pyridines, N,N-dimethyl-aniline, the tertiary alkylamines such as triethylamine, trimethylamine, etc., with or without inert cosolvents typified by methylene chloride, diethyl ether, benzene, tetrahydrofuran, or the like. The reaction temperature can range from about 0 C. to about 60 C. Room temperature is preferred, however.
The reaction product from the foregoing reaction is the desired 4-phenoxyalkanesulfonanilide (I) in which R is hydrogen or alkyl. The reaction product can be isolated from the reaction mixture in conventional manner, e.g., by filtration or extraction into a water-immiscible solvent, followed by washing and drying of the recovered product. If necessary, the product can be purified further by crystallization or by high vacuum distillation.
A 4-phenoxyalkanesulfonilide (I) where R is hydrogen can be alkylated by treatment, in an inert organic solvent such as benzene, tetrahydrofuran, or dioxane, with an alkylating agent which can be an alkyl halide or a sec.-aminoalkyl halide. The alkylation takes place in the presencepf a base, for example, an alkali metal alkoxide such as potassium tert.-butoxide, or an alkali metal hydride such as sodium hydride or potassium hydride. Reaction temperature for the alkylation reaction can range from about C. to about 100 C. When the alkylating agent is a primary alkyl iodide, room temperature is the preferred reaction temperature; however, for alkyl chlorides a temperature from about 50 C. to about 100 C. is preferred. When sec.-aminoalkyl halides in the form of a hydrohalide salt are employed as the alkylating agent, sufiicient base is added to the reaction mixture to liberate the free sec.-aminoalkyl halide and to form the sulfonanilide alkali metal salt.
Illustrative alkyl halides which can be used as alkylating agents are methyl iodide, ethyl iodide, propyl iodide, butyl iodide, methtyl bromide, ethyl chloride, propyl bromide, butyl chloride, sec.-butyl bromide, and the like.
Illustrative sec.-aminoalkyl halides suitable as alkylating agents are N,N-diethyl-2-chloroethylamine, N,N- dibutyl-2-chloro-ethylamine, N,N diethyl-3-chloropropylamine hydrochloride, N-methyl-N-propyl-3-bromopropylamine hydrochloride, N ethyl N-butyl-2-bromoethylamine, N-(Z-chloroethyl)piperidine, N-(3-chloropropyl) piperidine, N-(2-chloroethyl)pyrrolidine, N-(S-chloropropyl)pyrrolidine, N-(2-chloroethyl)morpholine, N-(3- chloropropyl)morpholine, and the like.
The compounds of the present invention where R is sec.-aminoalkyl are amines which can eXist either in the nonprotonated or free-base form, or in the protonated or acid addition salt form, depending on the pH of the environment. Stable, pharmaceutically acceptable protonates can be formed on neutralization of the free-base form with suitable acids such as hydrogen chloride, hydrogen bromide, sulfuric acid, phosphoric acid, acetic acid, and the like.
The compounds of this invention have lipid-normalizing activity and thus are useful as hypocholesterolemic agents and as hypotriglyceridemic agents in mammals.
For purposes of administration, the compounds of this invention can be combined with solid or liquid pharmaceutical carriers and formulated in the form of tablets, powder packets, or capsules, using starch or similar excipients. The instant compounds can also be dissolved or suspended in suitable solvents or vehicles for oral or parenteral administration. If desired, the present active ingredients can also be admixed with food.
The amount of the active ingredient that is to be administered depends on the age, weight, and condition of the recipient, and also on factors such as the frequency and route of administration.
The daily dose range can be from about 0.1 milligram per kilogram of body weight to about 50 milligrams per kilogram of body weight.
The present invention is further illustrated by the following examples.
EXAMPLE I Preparation of 4-phenoxymethanesulfonanilide p-Phenoxyaniline (about 37 grams) was dissolved in pyridine (about 100 milliliters). The resulting solution was chilled to about 5 C. and methanesulfonyl chloride (about 15 milliliters) was added thereto.
The resulting admixture was stirred at about room temperature for about 4 hours, then diluted with water and ice. A precipitate was observed to form and was recovered by filtration. Upon recrystallization from methanol, about 35 grams of a product melting at 125 C. to 126 C., and about 9 grams of the same product melting at 124 C.
4- to 126 C. was obtained. An analytical sample melting at 126.5 C. to 127.5 C. was obtained after two additional recrystallizations, using charcoal once. The product was identified as 4'-phenoxymethanesulfonanilide, obtained in about 83 percent yield.
Analysis.Calcd for C H NO S (percent): C, 59.30; H, 4.98; S, 12.18. Found (percent): C, 59.22; H, 4.76; S, 12.09.
In a manner similar to Example I, but using ethanesulfonyl chloride as one of the reactants, the corresponding 4-phenoxyethanesulfonanilide can be prepared;
Using propanesulfonyl chloride the corresponding 4'- phenoxypropanesulfonanilide can be prepared;
Using butanesulfonyl bromide the corresponding 4- phenoxybutanesulfonanilide can be prepared;
Using pentanesulfonyl chloride the corresponding 4'- phenoxypentanesulfonanilide can be prepared;
Using hexanesulfonyl chloride the corresponding 4- phenoxyhexanesulfonanilide can be prepared; etc.
Similarly, reacting p-(p-chlorophenoxy)aniline with; methanesulfonyl chloride the corresponding 4'-(4-chlorophenoxy)methanesulfonanilide is produced;
Reacting 3-chloro-4-phenoxyaniline with ethanesulfonyl chloride the corresponding 3-chloro-4-phenoxyethanesulfonanilide is produced;
Reacting 4-(p-chlorophenoxy)-3,5-diiodoaniline with propanesulfonyl chloride the corresponding 4'-(4-chlorophenoxy)-3,5-diiodopropanesulfonanilide is produced;
Reacting p (2,4,5 trichlorophenoxy)aniline with butanesulfonyl chloride the corresponding 4-(2,4,5-trichlorophenoxy)-butanesulfonanilide is produced;
Reacting p-(p-tert.-butylphenoxy)aniline with methanesulfonyl chloride the corresponding 4'-(4-tert.-butylphenoxy)-methanesulfonanilide is produced;
Reacting N-methyl-p-phenoxyaniline with methanesulfonyl chloride the corresponding N-methyl-4'-phenoxymethanesulfonanilide is produced;
Reacting N butyl 4-(2,4,6-trimethylphenoxy)aniline with ethanesulfonyl chloride the corresponding N-butyl- 4 (2,4,6 trimethylphenoxy)ethanesulfonanilide is produced;
Reacting N ethyl 4-(2,4,6-trimethylphenoxy)-3,5-diiodoaniline with propanesulfonyl chloride the corresponding N ethyl 4'-(2,4,6-trimethylphenoxy)-3',5'-diiodopropanesulfonanilide is produced;
Reacting 3,5-diiodo-4-(2-methoxyphenoxy)aniline with butanesulfonyl chloride the corresponding 3,5-diiodo- 4-(2-methoxyphenoxy)butanesulfonanilide is produced;
Reacting 3,5-dibromo-4 (3-butoxyphenoxy)aniline with methanesulfonyl chloride the corresponding 3,5 dibromo-4'-(3 butoxyphenoxy)methanesulfonanilide is produced, etc.
EXAMPLE II Preparation of N-methyl-4'-phen0xymethanesulfonanilide 4'-phenoxymethanesulfonanilide (about 10 grams) was dissolved in dry tetrahydrofuran (about milliliters). To the resulting solution was added potassium cert.- butoxide (about 4.5 grams) and methyl iodide (about 15 milliliters), and the produced admixture was stirred for about 4 hours, and then the tetrahydrofuran was removed by evaporation in vacuo. The obtained residue was dissolved in methylene chloride-water, and the produced organic layer was separated. The organic layer was washed well with dilute aqueous sodium hydroxide and Water, and then dried over magnesium sulfate. The dried organic layer was evaporated in vacuo and the produced solids recrystallized from ethyl acetate-mixed hexanes. About 7.7 grams of crystals melting at 112 C. to 113 C. was obtained. The crystals were identified as N-methyl-4'-phenoxymethanesulfonanilide, obtained in about 73 percent yield.
Analysis.-Calcd for C H NO S (percent): C, 60.63; H, 5.45; N, 5.05; S, 11.56. Found (percent): C, 60.56; H, 5.68; N, 5.17; S, 11.45.
EXAMPLE III Preparation of N-[Z-(diethylamino)ethyl]-4'- phenoxymethanesulfonanilide 4'-phenoxymethanesulfonanilide (about 16.75 grams), potassium tert.-butoxide (about 23.5 grams), N,N-diethyl 2-chloroethy1amine hydrochloride (about 22 grams), and dry tetrahydrofuran (about 200 milliliters) were admixed, stirred at about room temperature for about 4 hours, and then heated under reflux for about 30 hours.
Thereafter, the tetrahydrofuran Was removed by evaporation in vacuo, and the produced residue dissolved in methylene chloride-water. The obtained organic layer was separated and washed well with dilute aqueous sodium hydroxide and water, and then dried over sodium sulfate. The dried organic layer was evaporated in vacuo and the residue therefrom crystallized from ethyl alcoholwater.
About 10.6 grams of crystals melting at 71 C. to 75 C. and resolidifying and melting at 84 C. to 86 C. was obtained. One recrystallization from ethyl alcohol yielded crystals melting at 71 C. to 75 C. and resolidifying and melting at 86 C. to 87 C. The crystals were identified as N- [2-(diethylamino)ethyl]4 phenoxy methanesulfonanilide, obtained in about 46 percent yield.
Analysis.Calcd for C H N O S (percent): C, 62.95; H, 7.23; N, 7.73; S, 8.85. Found (percent): C, 62.92; H, 7.21; N, 7.73; S, 8.82.
In a manner similar to Example III but using N,N- dibutyl-2-chloroethylamine hydrochloride in lieu of N,N- diethyl-2-chloroethylamine hydrochloride the corresponding N-[Z-(dibutylamino)ethyl]-4' phenoxymethanesulfonanilide can be prepared;
Using N,Ndiethyl-3-chloropropylamine hydrochloride the corresponding N-[3-diethylamino)propyl] -4'-phenoxymethanesulfonanilide can be prepared.
Using N-methyl-N-propyl-3-chloropropylamine hydrochloride the corresponding N-[3-(N-methyl-N-propylamino)propyl]-4'-phenoxymethanesulfonanilide can be prepared;
Using N-(2-ch1oroethyl)piperidine the corresponding N-(2-piperidinoethyl)-4' phenoxyrnethanesulfonanilide can be prepared;
Using N-(3-chloropropyl)piperidine the corresponding N (3 piperidinopropyl) 4' phenoxymethanesulfonanilide can be prepared;
Using N-(2-chloroethyl)pyrrolidine the corresponding N-[2-(1-pyrrolidinyl)ethyl] 4 phenoxymethanesulfonanilide can be prepared;
Using N-(3-chloropropyl)pyrrolidine the corresponding N-[3-(1-pyrrolidinyl)propyl] 4'-phenoxymethanesulfonanilide can be prepared;
Using N-(2-chloroethyl)morpholine the corresponding N-(2-morpholinoethyl)-4' phenoxymethanesulfonanilide can be prepared;
formula o- 1 I-s 024a in n wherein X is a member of the grouping consisting of halo, alkyl containing from 1 to 4 carbon atoms, inclusive, and alkoxy containing from 1 to 4 carbon atoms, inclusive; Y is halo; R is a member of the grouping consisting of hydrogen, alkyl containing from 1 to 4 carbon atoms, inclusive, Z-piperidinoethyl, 3-piperidinopropyl, 2-( l-pyrrolidinyl ethyl, 3-( l-pyrrolidinyl) propyl, 2-morpholinoethyl, 3-morpholinopropyl, and dialkyl aminoalkyl of the formula RI --(CH2)k-N where R and R are alkyl containing from 1 to 4 carbon atoms, inclusive; R is alkyl containign from 1 to 6 carbon atoms, inclusive; m is an integer having a value of zero to 3, inclusive; n is an integer having a value of zero to 2, inclusive; and k is an integer having a value of 2 to 3, inclusive; and the corresponding pharmaceutically acceptable acid addition salts.
2. The 4-phenoxyalkanesulfonanilide in accordance with claim 1 wherein R is hydrogen, R is methyl, and m and n have a value of zero.
3. The 4'-phenoxyalkanesulfonanilide in accordance with claim 1 wherein R and R are methyl, and m and n have a value of zero.
4. The 4-phenoxyalkanesulfonanilide in accordance with claim 1 wherein R is dialkylaminoalkyl with R and R both ethyl and k has a value of 2, R is methyl, and mi and n have a value of zero.
References Cited UNITED STATES PATENTS 3,223,582 12/1965 Bindler et al. l6730 OTHER REFERENCES Smith, The Chemistry of Open Chain N-cpds. I (Benjamin, New York, 1965), p. 73.
HENRY R. JILES, Primary Examiner C. M. SHURKO, Assistant Examiner U.S. C1. X.R.
US654064A 1967-07-18 1967-07-18 4'-phenoxyalkanesulfonanilides Expired - Lifetime US3531522A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65406467A 1967-07-18 1967-07-18

Publications (1)

Publication Number Publication Date
US3531522A true US3531522A (en) 1970-09-29

Family

ID=24623305

Family Applications (1)

Application Number Title Priority Date Filing Date
US654064A Expired - Lifetime US3531522A (en) 1967-07-18 1967-07-18 4'-phenoxyalkanesulfonanilides

Country Status (5)

Country Link
US (1) US3531522A (en)
BE (1) BE718228A (en)
FR (1) FR1586894A (en)
GB (1) GB1204946A (en)
IL (1) IL30223A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673123A (en) * 1969-03-21 1972-06-27 Bayer Ag 2,2{40 ,4,4{40 -tetrachloro-5,5{40 -diamino-diphenyl ether
US4866091A (en) * 1986-12-31 1989-09-12 Fujisawa Pharmaceutical Co., Ltd. Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US5614536A (en) * 1993-01-13 1997-03-25 Roemmers S.A.I.C.F. Substituted N-aminoalkylmethane sulfanilide as antispasmodica

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845996A1 (en) * 1978-10-23 1980-04-30 Bayer Ag HERBICIDAL AGENTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING WEEDS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3223582A (en) * 1961-06-07 1965-12-14 Geigy Chem Corp Antimicrobic compositions and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3223582A (en) * 1961-06-07 1965-12-14 Geigy Chem Corp Antimicrobic compositions and use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673123A (en) * 1969-03-21 1972-06-27 Bayer Ag 2,2{40 ,4,4{40 -tetrachloro-5,5{40 -diamino-diphenyl ether
US4866091A (en) * 1986-12-31 1989-09-12 Fujisawa Pharmaceutical Co., Ltd. Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US5614536A (en) * 1993-01-13 1997-03-25 Roemmers S.A.I.C.F. Substituted N-aminoalkylmethane sulfanilide as antispasmodica

Also Published As

Publication number Publication date
FR1586894A (en) 1970-03-06
IL30223A (en) 1971-08-25
BE718228A (en) 1969-01-20
IL30223A0 (en) 1968-08-22
GB1204946A (en) 1970-09-09

Similar Documents

Publication Publication Date Title
ES2201048T3 (en) AMINOSULPHONYL CARBAMATES.
US5981595A (en) Sulfonyl urea and carbamate ACAT inhibitors
JPH075539B2 (en) Substituted sulfonamide benzamide and process for producing the same
US3634410A (en) Amides of benzoic acids with amine substituted piperidines
US3445472A (en) Mono- and di-aroyl pyridylethyl and piperidylethyl indoles
US4466964A (en) Lipid absorption-inhibiting 1,4-benzothiazines
US3706750A (en) Pyrrylaminoketone derivatives
DE69508875T2 (en) Amidinophenol derivatives as protease inhibiting compounds
KR19980071076A (en) 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
BE897828A (en) PIPERAZINE DERIVATIVES WITH ANTI-CHOLINERGIC AND / OR ANTI-HISTAMINE ACTIVITY.
EP0549796A1 (en) Diphenylpiperazine derivative and drug for circulatory organ containing the same
US4505921A (en) Sulfonylurea compounds and their use in treating diabetes
US3531522A (en) 4'-phenoxyalkanesulfonanilides
JPS609716B2 (en) 1,2-Benzinthiazolin-3-ones, their production method and use as medicine
DE69105786T2 (en) Urea derivatives, their preparation and pharmaceutical compositions containing them.
KR100348138B1 (en) Benzolactam derivatives
US4390537A (en) 1-(Substituted-aminoalkoxyphenyl)-2-methylene-1-alkanones, compositions and use
US4413011A (en) Substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides as anti-arteriosclerotic agents and method
US4397855A (en) 4-(Substituted)-α, α-dimethyl-1-piperazine pentanoic acids and derivatives as anti-arteriosclerotic agents and method
US2862965A (en) Pharmaceutical compounds
US3531523A (en) N-(phenoxyphenyl)sulfamides
US4271188A (en) Compounds having hypolipidaemic activity
FR2522000A1 (en) NOVEL THIOPYRANNOPYRIMIDINES, PARTICULARLY USEFUL AS HYPOGLYCEMIC AGENTS, AND THEIR MANUFACTURE
EP0230020A2 (en) 1,2,3,4,4a,9b-Hexahydro-4a-aminoalkyldibenzofurans, a process for their preparation and their use as medicaments
US3686291A (en) Thio derivatives of 2-hydroxy-3-naphthioc acid